Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone
2025

Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): Bae Sanghoon, Mai Van‐Hieu, Mun Seyoung, Dong Dalong, Han Kyudong, Park Sunghyouk, Hyun Jung Keun

Primary Institution: Dankook University

Hypothesis

Lonafarnib could reverse dexamethasone-induced muscle atrophy and restore muscle health to near-normal levels.

Conclusion

Lonafarnib mitigates dexamethasone-induced muscle atrophy by enhancing mitochondrial function and activating anabolic pathways.

Supporting Evidence

  • Lonafarnib significantly improved myotube area, fusion index, and diameter in C2C12 myotubes.
  • In C. elegans, lonafarnib increased the pharyngeal pumping rate, indicating enhanced neuromuscular function.
  • In DEX-induced atrophic rats, lonafarnib improved maximal grip strength and increased muscle weight.

Takeaway

Lonafarnib is a medicine that helps muscles stay strong and healthy, especially when they are getting weak from a medicine called dexamethasone.

Methodology

The study used in vitro models with C2C12 myotubes and in vivo models with Caenorhabditis elegans and DEX-treated Sprague–Dawley rats to assess the effects of lonafarnib on muscle atrophy.

Limitations

The use of dexamethasone-induced models may not fully replicate the complexities of natural aging or the multifactorial aetiology of sarcopenia.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/jcsm.13665

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication